ASX Small Cap Winners Sep 4-8

Valor Resources was the clear ASX small cap winner of the week, almost doubling in price to 2.5c.

Investors went on a buying frenzy Thursday when Valor revealed extraordinarily high copper and silver hits at its Berenguela project in Peru.

The stock (ASX:VAL) hit an all-time high of 2.9c before closing the week up 92 per cent at 2.5c.

The Perth-based company released high grade intercepts from one drill hole which included several intervals with silver grades exceeding the lab test limits of 4000 grams per tonne.

“The extraordinarily high copper and silver grades out of this drill hole further supports our view that Berenguela is shaping up to be a project of exceptional quality,” said Valor chairman Mark Sumner.

Magnetic Resources (ASX:MAU) was a close second with a jump of 85 per cent to 24c.

Magnetic reported on September 1 that prospectors had found fine grades of gold after digging and panning in the dirt on its Mertondale project in Central Western Australia.

“The prospectors report that a 1kg sample of laterite [sedimentary rock] within a hand dug pit contains visible gold … from panning,” Magnetic told the market.

“Follow up surface laterite sampling is expected to commence in the next few days, to be followed by drilling in September once the necessary permits have been obtained.”

Explorer Tungsten Mining (ASX:TGN) was the week’s third biggest small cap gainer, up 77 per cent to 17c – for no apparent reason other than a steady rise in the price of nature’s toughest metal.

Replying to an ASX speeding ticket query this week, TGN said it was “not aware” of any unannounced information concerning the company.

However the company — which had no revenue and $3.2 million in the bank at the end of June — noted the price of ammonium paratungstate (APT) had risen 35 per cent since June.

Tungsten is priced according to metric ton units of ATP — a crystalline material formed when ore is put through a chemical process. ATP is used to produce various materials required for end products such as wire and tools.

Gold explorer Mantle Mining (ASX:MNM) jumped 71 per cent for the week after announcing London-based resources venture capitalist InCoR had become a strategic investor, putting $1.5 million into the company.

Wifi provider Tomizone (ASX:TOM) gained 67 per cent after announcing a deal to buy Kiwi communications company Bluesky Online Services in a cash and scrip deal.

Here are the best performing ASX small cap stocks for Sep 4-8:

 

ASX Small Cap Losers Sep 4-8

The slow-motion car crash of telco software maker ZipTel dominated the bottom end of the table.

ZipTel (ASX:ZIP) dropped like a stone after sensationally retracting a “landmark” deal it announced last month and parting ways with controversial founder Keaton Wallace.

In a statement issued late on Friday afternoon, Ziptel said it “retracts, without any admission of liability, its announcement dated 9 August 2017 entitled ‘Ziptel signs landmark Revenue Share Agreement for Zipt IP’.”

The company had also “accepted the resignation of founder Keaton Wallace effective immediately”.

ZipTel’s shares plummeted by 45 per cent minutes after the stock resumed trading following the announcement.

It finished down 43 per cent at 2c.

Clancy Exploration (ASX:CLY) fell 33 per cent after resuming trade for the first time since July 11.

Back in June the explorer was granted exploration licences covering about 80 sq km of an Austrian cobalt-nickel site called Leogang.

Not long after, the company  “was made aware that a number of licences potentially had preceding priority claimants”.

After a long investigation and trade suspension Clancy figured out that about 15 per cent of its newly acquiring project area rights were in fact claimed by other parties – leaving it with 68 sq km.

Clancy had $1.5 million in the bank at the end of June .

Drug maker Acrux (ASX:ACR) was another notable loser this week, falling 29 per cent after US pharma giant Eli Lilly pulled out of a deal to distribute its only product — testosterone armpit applicator Axiron.

Axiron is used to treat adult males who have low or no testosterone.

Announced back in 2010, the deal was said to be the biggest ever Australian biotech licensing arrangement, worth up to $US335 million ($419m) plus royalties.

But the company said on Wednesday that its deal to license Axiron to Eli Lilly had been scrapped after regulatory changes in the US for testosterone products.

Here are the worst performing ASX small cap stocks for Sep 4-8: